vs
PTC Inc.（PTC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是PTC Inc.的1.1倍（$772.1M vs $685.8M），PTC Inc.净利率更高（24.3% vs 12.7%，领先11.5%），PTC Inc.同比增速更快（21.4% vs 5.9%），PTC Inc.自由现金流更多（$267.4M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 6.6%）
PTC是1985年成立的美国计算机软件与服务企业，总部位于马萨诸塞州波士顿。公司1988年率先推出参数化关联特征驱动的三维CAD建模软件，1998年发布基于互联网的产品生命周期管理（PLM）产品，目前面向合作伙伴与开发者提供物联网、增强现实（AR）平台及相关产品服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PTC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$685.8M
营收增速更快
PTC
高出15.5%
5.9%
净利率更高
PTC
高出11.5%
12.7%
自由现金流更多
PTC
多$105.6M
$161.8M
两年增速更快
RVTY
近两年复合增速
6.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $685.8M | $772.1M |
| 净利润 | $166.5M | $98.4M |
| 毛利率 | 82.8% | — |
| 营业利润率 | 32.2% | 14.5% |
| 净利率 | 24.3% | 12.7% |
| 营收同比 | 21.4% | 5.9% |
| 净利润同比 | 102.5% | 3.9% |
| 每股收益（稀释后） | $1.39 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PTCRVTY
| Q4 25 | $685.8M | $772.1M | ||
| Q3 25 | $893.8M | $698.9M | ||
| Q2 25 | $643.9M | $720.3M | ||
| Q1 25 | $636.4M | $664.8M | ||
| Q4 24 | $565.1M | $729.4M | ||
| Q3 24 | $626.5M | $684.0M | ||
| Q2 24 | $518.6M | $691.7M | ||
| Q1 24 | $603.1M | $649.9M |
净利润PTCRVTY
| Q4 25 | $166.5M | $98.4M | ||
| Q3 25 | $347.8M | $46.7M | ||
| Q2 25 | $141.3M | $53.9M | ||
| Q1 25 | $162.6M | $42.2M | ||
| Q4 24 | $82.2M | $94.6M | ||
| Q3 24 | $126.5M | $94.4M | ||
| Q2 24 | $69.0M | $55.4M | ||
| Q1 24 | $114.4M | $26.0M |
毛利率PTCRVTY
| Q4 25 | 82.8% | — | ||
| Q3 25 | 86.9% | 53.6% | ||
| Q2 25 | 82.9% | 54.5% | ||
| Q1 25 | 83.3% | 56.5% | ||
| Q4 24 | 80.2% | — | ||
| Q3 24 | 82.0% | 56.3% | ||
| Q2 24 | 78.4% | 55.7% | ||
| Q1 24 | 81.8% | 54.6% |
营业利润率PTCRVTY
| Q4 25 | 32.2% | 14.5% | ||
| Q3 25 | 48.5% | 11.7% | ||
| Q2 25 | 32.6% | 12.6% | ||
| Q1 25 | 35.1% | 10.9% | ||
| Q4 24 | 20.4% | 16.3% | ||
| Q3 24 | 31.0% | 14.3% | ||
| Q2 24 | 18.5% | 12.4% | ||
| Q1 24 | 29.8% | 6.8% |
净利率PTCRVTY
| Q4 25 | 24.3% | 12.7% | ||
| Q3 25 | 38.9% | 6.7% | ||
| Q2 25 | 21.9% | 7.5% | ||
| Q1 25 | 25.6% | 6.4% | ||
| Q4 24 | 14.6% | 13.0% | ||
| Q3 24 | 20.2% | 13.8% | ||
| Q2 24 | 13.3% | 8.0% | ||
| Q1 24 | 19.0% | 4.0% |
每股收益（稀释后）PTCRVTY
| Q4 25 | $1.39 | $0.86 | ||
| Q3 25 | $2.88 | $0.40 | ||
| Q2 25 | $1.17 | $0.46 | ||
| Q1 25 | $1.35 | $0.35 | ||
| Q4 24 | $0.68 | $0.77 | ||
| Q3 24 | $1.05 | $0.77 | ||
| Q2 24 | $0.57 | $0.45 | ||
| Q1 24 | $0.95 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $209.7M | $919.9M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $3.8B | $7.3B |
| 总资产 | $6.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.31× | — |
8季度趋势，按日历期对齐
现金及短期投资PTCRVTY
| Q4 25 | $209.7M | $919.9M | ||
| Q3 25 | $184.4M | $931.4M | ||
| Q2 25 | $199.3M | $991.8M | ||
| Q1 25 | $235.2M | $1.1B | ||
| Q4 24 | $196.3M | $1.2B | ||
| Q3 24 | $265.8M | $1.2B | ||
| Q2 24 | $247.7M | $2.0B | ||
| Q1 24 | $249.0M | $1.7B |
总债务PTCRVTY
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.5B | — |
股东权益PTCRVTY
| Q4 25 | $3.8B | $7.3B | ||
| Q3 25 | $3.8B | $7.4B | ||
| Q2 25 | $3.5B | $7.6B | ||
| Q1 25 | $3.4B | $7.6B | ||
| Q4 24 | $3.2B | $7.7B | ||
| Q3 24 | $3.2B | $7.9B | ||
| Q2 24 | $3.0B | $7.9B | ||
| Q1 24 | $2.9B | $7.8B |
总资产PTCRVTY
| Q4 25 | $6.4B | $12.2B | ||
| Q3 25 | $6.6B | $12.1B | ||
| Q2 25 | $6.2B | $12.4B | ||
| Q1 25 | $6.2B | $12.4B | ||
| Q4 24 | $6.1B | $12.4B | ||
| Q3 24 | $6.4B | $12.8B | ||
| Q2 24 | $6.1B | $13.4B | ||
| Q1 24 | $6.2B | $13.4B |
负债/权益比PTCRVTY
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 0.43× | — | ||
| Q1 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $269.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $267.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 39.0% | 21.0% |
| 资本支出强度资本支出/营收 | 0.3% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.62× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $888.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PTCRVTY
| Q4 25 | $269.7M | $182.0M | ||
| Q3 25 | $104.0M | $138.5M | ||
| Q2 25 | $243.9M | $134.3M | ||
| Q1 25 | $281.3M | $128.2M | ||
| Q4 24 | $238.4M | $174.2M | ||
| Q3 24 | $98.1M | $147.9M | ||
| Q2 24 | $213.8M | $158.6M | ||
| Q1 24 | $250.7M | $147.6M |
自由现金流PTCRVTY
| Q4 25 | $267.4M | $161.8M | ||
| Q3 25 | $100.5M | $120.0M | ||
| Q2 25 | $242.0M | $115.5M | ||
| Q1 25 | $278.5M | $112.2M | ||
| Q4 24 | $235.7M | $149.8M | ||
| Q3 24 | $93.6M | $125.6M | ||
| Q2 24 | $212.2M | $136.6M | ||
| Q1 24 | $247.1M | $129.7M |
自由现金流率PTCRVTY
| Q4 25 | 39.0% | 21.0% | ||
| Q3 25 | 11.2% | 17.2% | ||
| Q2 25 | 37.6% | 16.0% | ||
| Q1 25 | 43.8% | 16.9% | ||
| Q4 24 | 41.7% | 20.5% | ||
| Q3 24 | 14.9% | 18.4% | ||
| Q2 24 | 40.9% | 19.7% | ||
| Q1 24 | 41.0% | 20.0% |
资本支出强度PTCRVTY
| Q4 25 | 0.3% | 2.6% | ||
| Q3 25 | 0.4% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.4% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 0.7% | 3.3% | ||
| Q2 24 | 0.3% | 3.2% | ||
| Q1 24 | 0.6% | 2.7% |
现金转化率PTCRVTY
| Q4 25 | 1.62× | 1.85× | ||
| Q3 25 | 0.30× | 2.97× | ||
| Q2 25 | 1.73× | 2.49× | ||
| Q1 25 | 1.73× | 3.03× | ||
| Q4 24 | 2.90× | 1.84× | ||
| Q3 24 | 0.78× | 1.57× | ||
| Q2 24 | 3.10× | 2.87× | ||
| Q1 24 | 2.19× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PTC
| Support And Cloud Services | $393.3M | 57% |
| License | $269.7M | 39% |
| Technology Service | $22.9M | 3% |
| Perpetual License | $5.6M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
